Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia overview
Small molecule is under development for the treatment of schizophrenia. It is administered through the subcutaneous route. The drug candidate is a long acting injectable(LAI) formulation of ITI-007. It is developed based on drug discovery technology (ITI-007 Platform).
Intra-Cellular Therapies overview
Intra-Cellular Therapies (ICTI) carries out the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The company develops drugs for the treatment of heart failure, immune system regulation, neurodegenerative diseases, cancers and other non-CNS disorders. Its pipeline products include lumateperone (ITI-007) which is used for the treatment of schizophrenia, behavioral disturbances associated with dementia and Alzheimer’s disease, bipolar disorder and behavioral disturbances such as dementia and Alzheimer’s disease. ICTI is headquartered in New York City, New York, the US.
For a complete picture of Small Molecule to Antagonize 5-HT2A Receptor for Schizophrenia’s drug-specific PTSR and LoA scores, buy the report here.